Get started
Work

Supplementary Table S1 from Development of a Novel CLDN18.2-directed Monoclonal Antibody and Antibody–Drug Conjugate for Treatment of CLDN18.2-Positive Cancers

Year: 2023
Type: supplementary-materials
Abstract: Binding of CLDN18.2 mAbs to cell lines that either naturally express or are engineered to express CLDN18 isoforms
DOI: 10.1158/1535-7163.24709939
Authors: Neil A. O'Brien, Martina S.J. McDermott, Jun Zhang, Ke Wei Gong, Ming Lu, Benjamin Hoffstrom, Tong Luo, Raul Ayala, Kevin Chau, Min Liang, Athena M. Madrid, Timothy R. Donahue, John A. Glaspy, Leonard Presta, Dennis J. Slamon
Language: English
Field: Medicine
Open Access status: gold
OpenAlex ID: W4389242116
Cites:
Cited by:
Related to: 10